Mutant p53 reactivation by PRIMA-1MET induces multiple signaling pathways converging on apoptosis

被引:87
作者
Lambert, J. M. R. [1 ,2 ]
Moshfegh, A. [1 ]
Hainaut, P. [2 ]
Wiman, K. G. [1 ]
Bykov, V. J. N. [1 ]
机构
[1] Karolinska Inst, Dept Oncol Pathol, Canc Ctr Karolinska, SE-17176 Stockholm, Sweden
[2] Int Agcy Res Canc, Mol Carcinogenesis & Biomarkers Grp, F-69372 Lyon, France
关键词
cancer; mutant p53; apoptosis; novel therapy; ENDOPLASMIC-RETICULUM STRESS; UNFOLDED-PROTEIN RESPONSE; WILD-TYPE P53; TUMOR-SUPPRESSOR; P53-DEPENDENT APOPTOSIS; P53-INDUCED APOPTOSIS; TARGET GENES; CANCER-CELLS; CORE DOMAIN; ER STRESS;
D O I
10.1038/onc.2009.425
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The low molecular weight compound PRIMA-1(MET) reactivates mutant p53 and triggers mutant p53-dependent apoptosis in human tumor cells. We investigated the effect of PRIMA-1(MET) on global gene expression using microarray analysis of Saos-2 cells expressing His273 mutant p53 and parental p53 null Saos-2 cells. PRIMA-1(MET) affected transcription of a significantly larger number of genes in the mutant p53-expressing cells compared to the p53 null cells. Genes affected by PRIMA-1(MET) in a mutant p53-dependent manner include the cell-cycle regulators GADD45B and 14-3-3 gamma and the pro-apoptotic Noxa. Several of the affected genes are known p53 target genes and/or contain p53 DNA-binding motifs. We also found mutant p53-dependent disruption of the cytoskeleton, as well as transcriptional activation of the XBP1 gene and cleavage of its mRNA, a marker for endoplasmic reticulum stress. Our data show that PRIMA-1(MET) induces apoptosis through multiple transcription-dependent and -independent pathways. Such integral engagement of multiple pathways leading to apoptosis is consistent with restoration of wild-type properties to mutant p53 and is likely to reduce the risk of drug resistance development in clinical applications of PRIMA-1(MET). Oncogene (2010) 29, 1329-1338; doi:10.1038/onc.2009.425; published online 30 November 2009
引用
收藏
页码:1329 / 1338
页数:10
相关论文
共 48 条
[1]  
Abcouwer SF, 2002, INVEST OPHTH VIS SCI, V43, P2791
[2]   Worse survival for TP53 (p53)-mutated breast cancer patients receiving adjuvant CMF [J].
Andersson, J ;
Larsson, L ;
Klaar, S ;
Holmberg, L ;
Nilsson, J ;
Inganäs, M ;
Carlsson, G ;
Öhd, J ;
Rudenstam, CM ;
Gustavsson, B ;
Bergh, J .
ANNALS OF ONCOLOGY, 2005, 16 (05) :743-748
[3]   Dynamic interaction of BiP and ER stress transducers in the unfolded-protein response [J].
Bertolotti, A ;
Zhang, YH ;
Hendershot, LM ;
Harding, HP ;
Ron, D .
NATURE CELL BIOLOGY, 2000, 2 (06) :326-332
[4]   Disruption of p53 in human cancer cells alters the responses to therapeutic agents [J].
Bunz, F ;
Hwang, PM ;
Torrance, C ;
Waldman, T ;
Zhang, YG ;
Dillehay, L ;
Williams, J ;
Lengauer, C ;
Kinzler, KW ;
Vogelstein, B .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (03) :263-269
[5]   PRIMA-1MET synergizes with cisplatin to induce tumor cell apoptosis [J].
Bykov, VJN ;
Zache, N ;
Stridh, H ;
Westman, J ;
Bergman, J ;
Selivanova, G ;
Wiman, KG .
ONCOGENE, 2005, 24 (21) :3484-3491
[6]   Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound [J].
Bykov, VJN ;
Issaeva, N ;
Shilov, A ;
Hultcrantz, M ;
Pugacheva, E ;
Chumakov, P ;
Bergman, J ;
Wiman, KG ;
Selivanova, G .
NATURE MEDICINE, 2002, 8 (03) :282-288
[7]   The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth [J].
Cadwell, C ;
Zambetti, GP .
GENE, 2001, 277 (1-2) :15-30
[8]   P53-DEPENDENT APOPTOSIS IN THE ABSENCE OF TRANSCRIPTIONAL ACTIVATION OF P53-TARGET GENES [J].
CAELLES, C ;
HELMBERG, A ;
KARIN, M .
NATURE, 1994, 370 (6486) :220-223
[9]   Repression of new p53 targets revealed by ChIP on chip experiments [J].
Ceribelli, Michele ;
Alcalay, Myriam ;
Vigano, Maria Alessandra ;
Mantovani, Roberto .
CELL CYCLE, 2006, 5 (10) :1102-1110
[10]   Pharmacologic activation of p53 elicits Bax-dependent apoptosis in the absence of transcription [J].
Chipuk, JE ;
Maurer, U ;
Green, DR ;
Schuler, M .
CANCER CELL, 2003, 4 (05) :371-381